Altamira Therapeutics Ltd (CYTO) Return on Investment ROI from the fourth quarter of 2023 to fourth quarter of 2022 and for the year 2023, average high and low, overall ranking from Dec 31 2023 to Dec 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Altamira Therapeutics Ltd   (NASDAQ: CYTO)


Altamira Therapeutics Ltd's ROI from its fourth quarter of 2023 to the fourth quarter of 2022 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Altamira Therapeutics Ltd's ROI in the fourth quarter of 2023?


Within the Healthcare sector 909 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2023 from 0 to 4776.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2023)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2022)
IV. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 8 7 7 8 0
Return On Investment (TTM) 0 % -468.8 % -774.38 % -1510.91 % 1298.29 %
CYTO's Overall Ranking # 4776 # 0 # 0 # 0 # 5648
Seq. Investment Change TTM 32.88 % 65.18 % 95.11 % - -
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 0 -27 -27 -27 -27

CYTO Company Profile >> Back to CYTO Roi Comparisons >> See Annual CYTO Return On Investment



Return On Investment CYTO's Ranking
Within: No.
Industry # 429
Sector # 910
Overall # 4776

Return On Investment Statistics
High Average Low
193.92 %
44.13 %
-128.83 %
(Dec 31 2018)   (Dec 31 2024)







Financial Statements
Altamira Therapeutics Ltd's IV. Quarter Investments $ 8 Millions CYTO's Balance sheet
Altamira Therapeutics Ltd's IV. Quarter Income $ 0 Millions Quarterly CYTO's Income Statement
CYTO's Income by Division See CYTO's Income by Division


CYTO Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Investments in Millions 7 8 -7 16 20
Y / Y Investment Growth -18.16 % - - -22.16 % 169.85 %
Net Income in Millions -8 -4 -28 19 9
Y / Y Net Income Growth - - - 113.42 % 30.98 %
Annual Return On Investment -128.83 % -53.68 % - 119.73 % 43.67 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CYTO's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CYTO's Competitors
Subscribers only: Roi for Altamira Therapeutics Ltd's Suppliers
Subscribers only: Return On Investment for CYTO's Customers

Other Ratios
CYTO's Roa CYTO's Inventory Turnover Ratio CYTO's Growth Rates CYTO's Dividend Statistics
CYTO's Profitability Ratios CYTO's Asset Turnover Ratio CYTO's Dividend Growth
CYTO's Roe CYTO's Valuation Ratios CYTO's Financial Strength Ratios CYTO's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2023, within Healthcare Sector ROI

Date modified: 2026-09-02T17:46:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.